RU2502520C2 - Фармацевтическая композиция и относящиеся способы - Google Patents
Фармацевтическая композиция и относящиеся способы Download PDFInfo
- Publication number
- RU2502520C2 RU2502520C2 RU2010106661/15A RU2010106661A RU2502520C2 RU 2502520 C2 RU2502520 C2 RU 2502520C2 RU 2010106661/15 A RU2010106661/15 A RU 2010106661/15A RU 2010106661 A RU2010106661 A RU 2010106661A RU 2502520 C2 RU2502520 C2 RU 2502520C2
- Authority
- RU
- Russia
- Prior art keywords
- seq
- insulin
- composition
- alpha
- amino acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 33
- 239000008194 pharmaceutical composition Substances 0.000 title claims 27
- 239000000203 mixture Substances 0.000 claims abstract 69
- 239000003112 inhibitor Substances 0.000 claims abstract 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 26
- 239000003937 drug carrier Substances 0.000 claims abstract 23
- 239000012190 activator Substances 0.000 claims abstract 16
- 206010072170 Skin wound Diseases 0.000 claims abstract 15
- 239000011780 sodium chloride Substances 0.000 claims abstract 13
- 239000008365 aqueous carrier Substances 0.000 claims abstract 12
- 239000003814 drug Substances 0.000 claims abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 107
- 108090001061 Insulin Proteins 0.000 claims 40
- 102000004877 Insulin Human genes 0.000 claims 40
- 229940125396 insulin Drugs 0.000 claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- 239000004026 insulin derivative Substances 0.000 claims 18
- 125000000539 amino acid group Chemical group 0.000 claims 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 201000004624 Dermatitis Diseases 0.000 claims 12
- 150000001768 cations Chemical class 0.000 claims 12
- 230000035876 healing Effects 0.000 claims 12
- 101001011741 Bos taurus Insulin Proteins 0.000 claims 9
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 9
- 108010005991 Pork Regular Insulin Proteins 0.000 claims 9
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 claims 9
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 9
- WHOOZDLAJIKMBZ-UHFFFAOYSA-N 3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(CCCN(C)C)C=C1C1=C(C=2C3=CC=CC=C3N(C)C=2)C(=O)NC1=O WHOOZDLAJIKMBZ-UHFFFAOYSA-N 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- VWVYILCFSYNJHF-UHFFFAOYSA-N Goe 6976 Chemical compound C1=CC=C2N(CCC#N)C3=C4N(C)C5=CC=CC=C5C4=C(C(=O)NC4)C4=C3C2=C1 VWVYILCFSYNJHF-UHFFFAOYSA-N 0.000 claims 8
- 108010073961 Insulin Aspart Proteins 0.000 claims 8
- 108010057186 Insulin Glargine Proteins 0.000 claims 8
- 108010065920 Insulin Lispro Proteins 0.000 claims 8
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 8
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims 8
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims 8
- NMYKBZSMOUFOJV-FJSWQEPZSA-N aprinocarsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 NMYKBZSMOUFOJV-FJSWQEPZSA-N 0.000 claims 8
- 229950004932 aprinocarsen Drugs 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 229960004717 insulin aspart Drugs 0.000 claims 8
- 229960002869 insulin glargine Drugs 0.000 claims 8
- SAWVGDJBSPLRRB-UHFFFAOYSA-N methanesulfonic acid;3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate Chemical class CS(O)(=O)=O.C12=CC=CC=C2N(C)C=C1C1=C(C=2C3=CC=CC=C3N(CCCSC(N)=N)C=2)C(=O)NC1=O SAWVGDJBSPLRRB-UHFFFAOYSA-N 0.000 claims 8
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 8
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 7
- 206010052428 Wound Diseases 0.000 claims 7
- 208000027418 Wounds and injury Diseases 0.000 claims 7
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims 7
- 229960002068 insulin lispro Drugs 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- NOVSBNOTERYJBO-UHFFFAOYSA-N CCCCCC(=O)N.O.Cl.Cl Chemical compound CCCCCC(=O)N.O.Cl.Cl NOVSBNOTERYJBO-UHFFFAOYSA-N 0.000 claims 1
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 101100181139 Drosophila melanogaster Pkcdelta gene Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000007836 KH2PO4 Substances 0.000 abstract 1
- -1 Mg2+ cations Chemical class 0.000 abstract 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 abstract 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 229910000397 disodium phosphate Inorganic materials 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 abstract 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96270607P | 2007-07-30 | 2007-07-30 | |
| US60/962,706 | 2007-07-30 | ||
| PCT/IL2008/001049 WO2009016629A2 (en) | 2007-07-30 | 2008-07-30 | Pharmaceutical composition for treating wounds and related methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013142159/15A Division RU2013142159A (ru) | 2007-07-30 | 2013-09-16 | Фармацевтическая композиция |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010106661A RU2010106661A (ru) | 2011-09-10 |
| RU2502520C2 true RU2502520C2 (ru) | 2013-12-27 |
Family
ID=40305016
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010106661/15A RU2502520C2 (ru) | 2007-07-30 | 2008-07-30 | Фармацевтическая композиция и относящиеся способы |
| RU2013142159/15A RU2013142159A (ru) | 2007-07-30 | 2013-09-16 | Фармацевтическая композиция |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013142159/15A RU2013142159A (ru) | 2007-07-30 | 2013-09-16 | Фармацевтическая композиция |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20100310542A1 (https=) |
| EP (2) | EP2185184A2 (https=) |
| JP (3) | JP5411857B2 (https=) |
| KR (2) | KR20130121678A (https=) |
| CN (2) | CN102755649A (https=) |
| AU (1) | AU2008281374B2 (https=) |
| CA (1) | CA2694927A1 (https=) |
| NZ (1) | NZ582556A (https=) |
| RU (2) | RU2502520C2 (https=) |
| WO (1) | WO2009016629A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2766292C1 (ru) * | 2021-08-05 | 2022-03-14 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) | Состав вакцины против covid-19 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013885A2 (en) | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| EP2452686A3 (en) * | 2005-08-29 | 2012-09-05 | HealOr Ltd. | Methods and compositions for prevention and treatment of diabetic and aged skin |
| WO2011011808A1 (en) * | 2009-07-30 | 2011-02-03 | Roman Buga | A cosmetic composition comprising sodium chloride in combination with one or more of protein, collagen, gelatin or amino acid |
| US8889615B2 (en) | 2009-12-31 | 2014-11-18 | New York University | Methods for promoting epithelialization and healing of chronic wounds |
| EP2523677A2 (en) * | 2010-01-11 | 2012-11-21 | Healor Ltd. | Method for treatment of inflammatory disease and disorder |
| AU2011327785A1 (en) * | 2010-11-08 | 2013-03-07 | Healor Ltd. | Buffered ophthalmic compositions and methods of use thereof |
| US10342891B2 (en) * | 2013-09-19 | 2019-07-09 | Medline Industries, Inc. | Wound dressing containing saccharide and collagen |
| EP3501531A1 (en) | 2014-01-29 | 2019-06-26 | Université de Strasbourg | New target for diabetes treatment and prevention |
| EP3421485A1 (en) | 2017-06-30 | 2019-01-02 | Université de Strasbourg | Peptides for treatment and prevention of hyperglycaemia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124503A1 (en) * | 2001-12-28 | 2003-07-03 | Olivencia-Yurvati Albert H. | Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof |
| RU2002131487A (ru) * | 2002-11-25 | 2004-05-27 | Эдуард Валентинович Фрончек | Медицинский материал и изделия на его основе |
| WO2007026356A2 (en) * | 2005-08-29 | 2007-03-08 | Healor Ltd. | Methods and compositions for prevention and treatment of diabetic and aged skin |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3549747A (en) * | 1968-02-20 | 1970-12-22 | Flow Pharma Inc | Contact lens wetting solution and method of using same |
| US3947573A (en) * | 1969-12-01 | 1976-03-30 | Burton, Parsons And Company, Inc. | Opthalmic solution |
| US3856919A (en) * | 1970-06-08 | 1974-12-24 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3767788A (en) * | 1970-06-08 | 1973-10-23 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3767789A (en) * | 1971-06-21 | 1973-10-23 | Burton Parsons & Co Inc | Method of providing a synthetic mucus in vivo |
| US3987163A (en) * | 1973-07-27 | 1976-10-19 | Burton, Parsons And Company, Inc. | Polystyrene sulfonate containing opthalmic solutions |
| US3907985A (en) * | 1973-07-27 | 1975-09-23 | Burton Parsons And Company Inc | Polystyrene sulfonate containing opthalmic solutions |
| US4029817A (en) * | 1973-09-24 | 1977-06-14 | Allergan Pharmaceuticals | Soft contact lens preserving solutions |
| US3920810A (en) * | 1974-04-23 | 1975-11-18 | Burton Parsons And Company Inc | Polyacrylamide containing ophthalmic solutions |
| US4120949A (en) * | 1977-10-05 | 1978-10-17 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4131651A (en) * | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
| US4409205A (en) * | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4558033A (en) * | 1983-06-06 | 1985-12-10 | Amgen | Potentiation of the effects of insulin by peptides |
| US4673649A (en) * | 1983-07-15 | 1987-06-16 | University Patents, Inc. | Process and defined medium for growth of human epidermal keratinocyte cells |
| DE3674883D1 (de) * | 1985-11-25 | 1990-11-15 | Wako Pure Chem Ind Ltd | Farbentwicklungsmethode in klinischen untersuchungen. |
| US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
| US4833257A (en) * | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
| IL80298A (en) * | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| JPH0739508B2 (ja) * | 1986-11-11 | 1995-05-01 | 株式会社林原生物化学研究所 | プルラン・ポリエチレングリコ−ル会合物とその製造方法並びに用途 |
| US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
| US5137734A (en) * | 1989-03-22 | 1992-08-11 | Dana Farber Cancer Institute | Angiogenic monoglycerides |
| US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| US5158935A (en) * | 1989-05-12 | 1992-10-27 | Chiron Corporation | Human epidermal growth factor having substitution at position 11 |
| US5723119A (en) * | 1989-07-28 | 1998-03-03 | Schering Corporation | Method for enhancing wound healing/repair with IL-4 |
| US5145679A (en) * | 1989-10-05 | 1992-09-08 | Hinson Joan B | Topical emollient for prevention and treatment of circulatory induced lesions |
| US5981606A (en) * | 1991-03-01 | 1999-11-09 | Warner-Lambert Company | Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same |
| AU668509B2 (en) * | 1991-04-19 | 1996-05-09 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
| HUT67319A (en) * | 1991-08-30 | 1995-03-28 | Life Medical Sciences Inc | Compositions for treating wounds |
| US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
| AU3062392A (en) * | 1991-11-04 | 1993-06-07 | Novo Nordisk A/S | Pdgf gel formulation |
| US6537973B1 (en) * | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
| US5922686A (en) * | 1992-03-16 | 1999-07-13 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of protein kinase C |
| DE4208552A1 (de) * | 1992-03-17 | 1993-09-23 | Liedtke Pharmed Gmbh | Topische arzneiformen mit insulin |
| GB9210574D0 (en) * | 1992-05-18 | 1992-07-01 | Ca Nat Research Council | Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications |
| CA2125060C (en) * | 1993-07-02 | 1999-03-30 | Henry P. Dabrowski | Ophthalmic solution for artificial tears |
| US6028118A (en) * | 1996-08-08 | 2000-02-22 | Les Laboratoires Aeterna Inc. | Methods of using extracts of shark cartilage |
| JP3414539B2 (ja) * | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| US5631245A (en) * | 1995-06-06 | 1997-05-20 | Biodynamics Pharmaceuticals, Inc. | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions |
| GB2304047A (en) * | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
| DK0877752T3 (da) * | 1996-01-23 | 2003-09-15 | Univ Leland Stanford Junior | Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler |
| US5869037A (en) * | 1996-06-26 | 1999-02-09 | Cornell Research Foundation, Inc. | Adenoviral-mediated gene transfer to adipocytes |
| JPH10158188A (ja) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | 角膜治療用組成物 |
| GB9702943D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Wound healing |
| US6274712B1 (en) * | 1997-12-23 | 2001-08-14 | 3-Dimensional Pharmaceuticals, Inc. | Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137 |
| FR2773075B1 (fr) * | 1997-12-31 | 2000-05-05 | Cird Galderma | Utilisation d'activateurs de ppar-gamma en dermatologie |
| WO1999034821A1 (en) * | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| US6790207B2 (en) * | 1998-06-04 | 2004-09-14 | Curon Medical, Inc. | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
| US6489306B2 (en) * | 1998-02-23 | 2002-12-03 | University Of South Florida | Method of intranasal gene transfer for protection against respiratory infection |
| DE19826628C1 (de) * | 1998-06-17 | 2000-07-20 | Werner Kern | Intranasale Verwendung von Insulin bei Hirnleistungsstörungen |
| US6376467B1 (en) * | 1998-10-09 | 2002-04-23 | The Regents Of The University Of California | Use of inhibitors of protein kinase C epsilon to treat pain |
| IL141021A0 (en) * | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| US6096288A (en) * | 1998-10-12 | 2000-08-01 | Mobil Oil Corporation | Synthesis of the cubic mesoporous molecular sieve MCM-48 |
| WO2000030628A2 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
| US7261881B1 (en) * | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
| US6541447B1 (en) * | 1999-09-01 | 2003-04-01 | B & M Healthcare Technologies, Inc. | Wound healing composition and method for use thereof |
| NZ521437A (en) * | 2000-02-25 | 2004-04-30 | Immunex Corp | Integrin antagonists suitable as inhibitors of angiogenesis |
| IL151833A0 (en) * | 2000-03-24 | 2003-04-10 | Novartis Ag | Improved treatment of neovascularization |
| US6582713B2 (en) * | 2000-04-06 | 2003-06-24 | Univ. Of Colorado - Colorado Springs | Compositions and methods for promoting wound healing |
| US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
| CA2416788A1 (en) * | 2000-07-31 | 2002-02-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds |
| US20100129332A1 (en) * | 2000-07-31 | 2010-05-27 | Tamar Tennenbaum | Methods and pharmaceutical compositions for healing wounds |
| US20040037828A1 (en) * | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
| GB2369572A (en) * | 2000-11-29 | 2002-06-05 | Raft Trustees Ltd | Wound treatment composition comprising insulin |
| US20020119914A1 (en) * | 2000-12-26 | 2002-08-29 | Deguang Zhu | New uses of insulin and pancreatin |
| JP2002198443A (ja) * | 2000-12-26 | 2002-07-12 | Nec Corp | 半導体装置及びその製造方法 |
| GB0103877D0 (en) * | 2001-02-16 | 2001-04-04 | King S College London | Novel Drug Delivery system |
| DE10109280A1 (de) * | 2001-02-26 | 2002-09-05 | Peter Mayser | Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen |
| KR100404072B1 (ko) * | 2001-03-12 | 2003-11-03 | 주식회사 두산 | 광범위 피부질환 치료용 조성물 |
| US20030091601A1 (en) * | 2001-11-13 | 2003-05-15 | Abat Inc. | Use of topical arginine to enhance wound healing |
| WO2003059396A1 (en) * | 2002-01-11 | 2003-07-24 | Sergei Zolotukhin | Adiponectin gene therapy |
| RU2249467C2 (ru) * | 2002-11-25 | 2005-04-10 | ООО Научно-производственное предприятие "ЭРЛОН", Лтд. | Медицинский материал и изделия на его основе |
| US20040175384A1 (en) * | 2003-12-12 | 2004-09-09 | Mohapatra Shyam S. | Protein kinase C as a target for the treatment of respiratory syncytial virus |
| SE0300207D0 (sv) * | 2003-01-29 | 2003-01-29 | Karolinska Innovations Ab | New use and composition |
| US7190893B2 (en) * | 2003-06-27 | 2007-03-13 | Valeo Electrical Systems, Inc. | Fluid heater with low porosity thermal mass |
| NZ588743A (en) * | 2003-07-15 | 2012-05-25 | Univ Bar Ilan | Use of a protein kinase C (PKC) alpha inhibitor for treating inflammation of the skin |
| WO2005013885A2 (en) * | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| US20050164323A1 (en) * | 2003-12-24 | 2005-07-28 | Wyeth | Methods of treating asthma |
| US7902330B2 (en) * | 2004-02-13 | 2011-03-08 | Albert Einstein College Of Medicine Of Yeshiva University | Protein kinase inhibitors and methods for identifying same |
| EP1877424A4 (en) * | 2005-04-11 | 2010-09-29 | Pharmagap Inc | INHIBITORS OF PROTEIN KINASES AND USES THEREOF |
| WO2007016777A1 (en) * | 2005-08-05 | 2007-02-15 | Pharmagap Inc. | Targeted protein kinase c inhibitors and uses thereof |
| EP1931327B1 (en) * | 2005-08-19 | 2016-08-17 | Emisphere Technologies, Inc. | Cyclopropyl compounds and compositions for delivering active agents |
| US20090306045A1 (en) * | 2005-12-22 | 2009-12-10 | Ira Mellman | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease |
| US20080292726A1 (en) * | 2007-01-23 | 2008-11-27 | Bernstein Lawrence R | Ophthalmic gallium compositions and methods of their use |
| US20110223177A1 (en) * | 2008-09-09 | 2011-09-15 | University Of East Anglia | Treatment of fibrotic eye disorders |
| CA2751156A1 (en) * | 2009-02-24 | 2010-09-02 | Healor Ltd. | Visfatin therapeutic agents for the treatment of acne and other conditions |
-
2008
- 2008-07-30 CN CN2012102198145A patent/CN102755649A/zh active Pending
- 2008-07-30 WO PCT/IL2008/001049 patent/WO2009016629A2/en not_active Ceased
- 2008-07-30 CA CA2694927A patent/CA2694927A1/en not_active Abandoned
- 2008-07-30 EP EP08789725A patent/EP2185184A2/en not_active Withdrawn
- 2008-07-30 KR KR1020127028542A patent/KR20130121678A/ko not_active Ceased
- 2008-07-30 CN CN2008801012390A patent/CN101835486B/zh not_active Expired - Fee Related
- 2008-07-30 US US12/451,625 patent/US20100310542A1/en not_active Abandoned
- 2008-07-30 NZ NZ582556A patent/NZ582556A/xx not_active IP Right Cessation
- 2008-07-30 RU RU2010106661/15A patent/RU2502520C2/ru not_active IP Right Cessation
- 2008-07-30 AU AU2008281374A patent/AU2008281374B2/en not_active Ceased
- 2008-07-30 JP JP2010518808A patent/JP5411857B2/ja not_active Expired - Fee Related
- 2008-07-30 EP EP12007936.3A patent/EP2653166A3/en not_active Withdrawn
- 2008-07-30 KR KR1020107002645A patent/KR20100040912A/ko not_active Ceased
-
2013
- 2013-02-15 US US13/768,555 patent/US20140227243A1/en not_active Abandoned
- 2013-02-15 US US13/768,583 patent/US20130336952A1/en not_active Abandoned
- 2013-03-06 JP JP2013044384A patent/JP2013144697A/ja active Pending
- 2013-09-16 RU RU2013142159/15A patent/RU2013142159A/ru not_active Application Discontinuation
- 2013-10-25 JP JP2013221921A patent/JP2014024862A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124503A1 (en) * | 2001-12-28 | 2003-07-03 | Olivencia-Yurvati Albert H. | Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof |
| RU2002131487A (ru) * | 2002-11-25 | 2004-05-27 | Эдуард Валентинович Фрончек | Медицинский материал и изделия на его основе |
| WO2007026356A2 (en) * | 2005-08-29 | 2007-03-08 | Healor Ltd. | Methods and compositions for prevention and treatment of diabetic and aged skin |
Non-Patent Citations (1)
| Title |
|---|
| DULLBECCO, R. et al. (1954): Plaque formation and isolation of pure lines with poliomyelitis viruses. In: J. Exp.Med. vol. 99 (2), pp.167-182. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2766292C1 (ru) * | 2021-08-05 | 2022-03-14 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) | Состав вакцины против covid-19 |
| WO2023014245A1 (ru) * | 2021-08-05 | 2023-02-09 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства | Состав вакцины против covid-19 vaccine composition against covid-19 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100310542A1 (en) | 2010-12-09 |
| WO2009016629A3 (en) | 2009-05-22 |
| CN101835486B (zh) | 2012-12-12 |
| EP2185184A2 (en) | 2010-05-19 |
| JP2014024862A (ja) | 2014-02-06 |
| EP2653166A2 (en) | 2013-10-23 |
| US20140227243A1 (en) | 2014-08-14 |
| AU2008281374A1 (en) | 2009-02-05 |
| AU2008281374B2 (en) | 2012-05-31 |
| CN101835486A (zh) | 2010-09-15 |
| RU2013142159A (ru) | 2015-03-27 |
| HK1148467A1 (en) | 2011-09-09 |
| US20130336952A1 (en) | 2013-12-19 |
| NZ582556A (en) | 2013-02-22 |
| JP2010535194A (ja) | 2010-11-18 |
| KR20100040912A (ko) | 2010-04-21 |
| KR20130121678A (ko) | 2013-11-06 |
| JP5411857B2 (ja) | 2014-02-12 |
| WO2009016629A2 (en) | 2009-02-05 |
| CN102755649A (zh) | 2012-10-31 |
| JP2013144697A (ja) | 2013-07-25 |
| RU2010106661A (ru) | 2011-09-10 |
| EP2653166A3 (en) | 2014-08-27 |
| CA2694927A1 (en) | 2009-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2502520C2 (ru) | Фармацевтическая композиция и относящиеся способы | |
| KR101512377B1 (ko) | 골 아나볼릭 단백질을 위한 약물 전달 방법 | |
| EP2120859B1 (en) | Sustained-release formulations comprising bmp-7 crystals | |
| CN1198644C (zh) | 人甲状旁腺激素药物组合物 | |
| US11318230B2 (en) | Platelet-derived growth factor compositions and methods of use thereof | |
| Wen et al. | Dental stem cell dynamics in periodontal ligament regeneration: from mechanism to application | |
| US6719992B2 (en) | Non-aqueous surfactant-containing formulations for extended release of somatotropin | |
| WO2002083120A3 (en) | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | |
| EP2926826B1 (en) | Bone morphogenic protein binding peptide | |
| RU2739078C2 (ru) | Стабильные водные композиции белка MIA/CD-RAP | |
| CA2601304A1 (en) | Controlled release formulations of octreotide | |
| CN1216472A (zh) | 包含生长激素,氨基酸和非离子去污剂的药物配方 | |
| Machado-Silva et al. | Therapeutic uses for Angiotensin-(1-7) | |
| IL299024B1 (en) | Tpp1 formulations and methods for treating cln2 disease | |
| EP3498291A1 (en) | Pharmaceutical composition and biomaterial comprising fusion peptide having parathyroid hormone (pth) conjugated with peptide selective for bone tissue | |
| JP2003532636A5 (https=) | ||
| EP2445512B1 (en) | Enhancement of bmp retention | |
| WO2005072403A2 (en) | Bone morphogenic protein binding peptide | |
| IT9020144A1 (it) | Composizione farmaceutica contenente egf | |
| RU2009108643A (ru) | Лекарственные средства, усиливающие репарацию спинномозговых нервов, содержащие в качестве активного ингредиента грелин или его производные или вещества, которые действуют на ghs-r1а | |
| CA2529983A1 (en) | Preoperative treatment of post operative pain | |
| WO2007110079A3 (en) | Targeted delivery of fgfr ligands into the brain | |
| JPH03206040A (ja) | 注射用溶液及びその調製方法 | |
| US5922677A (en) | Therapeutic method and compounds of use therein | |
| Busch et al. | An overview of autonomic regulation of parotid gland activity: influence of orchiectomy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150731 |